Thursday 13th of January 2022 05:19:57 AM

Amgen, AstraZeneca's Tezspire now available in U.S. for severe asthma

Woman hand holding asthma inhaler ready to use in winter AntonioGuillem/iStock via Getty Images
  • Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) announce TEZSPIRE (tezepelumab-ekko) is now available for shipment to wholesalers in the U.S.
  • TEZSPIRE was approved by the FDA on Dec. 17, 2021 for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.


Top gainers today
Top losers today